Topigen adds $25M in new venture funds

Canada's Topigen Pharmaceuticals has gained $25 million in venture support for its clinical programs in respiratory disorders. The round brings the biotech's total financing to $71 million to date. The investment is earmarked for Phase II clinical programs relating to its lead products, TPI 1020, a small-molecule drug in development for Chronic Obstructive Pulmonary Disease and TPI ASM8, its RNA-inhibiting therapeutic for asthma.

In this round, new investors NovaQuest and MMV Financial join the existing venture investors: BDC Venture Capital, Desjardins Venture Capital, Caisse de Dépot et Placement du Québec, T2C2/BIO 2000 and Lothian Partners 27 SICAR. Additional funds and investors may be added to this financing.

 

- see the release for more information

ALSO: Quaker BioVentures has led a $13 million Series C round for EKR Therapeutics. Launched last summer, EKR markets a pain drug. Release

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.